IDEAL: Efficacy of Porcine Placental Extracellular Matrix Augmented Plus Standard of Care (SOC) Versus SOC Alone for the Management of Diabetic Foot Ulcers

Part of paid clinical trials in Los Angeles, California.

Sponsor
ConvaTec Inc.
Study ID
NCT06616844
Status
Recruiting

Conditions

  • Ulcer
  • Wound Heal

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • InnovaMatrix® AC — DEVICE
    SOC plus weekly application of the study device

Study Details

A multi-center, prospective, observer-blinded, randomized controlled clinical trial to evaluate the efficacy of PPECM augmented standard of care versus standard of care alone in the management of hard-to-heal diabetic foot ulcers.

Key Dates

Start date
Feb 12, 2025
Status verified
Mar 2025
Primary completion
Feb 28, 2026
Completion
Jul 31, 2026

Study Design

Enrollment
194 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • No Intervention: Standard of Care (SOC)
    Wound cleansing, using sterile saline, a non-ionic cleanser or a hypochlorous solution. Antiseptic agents including hydrogen peroxide, acetic acid, chlorhexidine, povidone/iodine, and cetrimide should not be used. Topical antimicrobials and silver dressings are also prohibited; Wound bed debridement, if clinically indicated. Primary wound dressings including a non-adherent, standard foam pad with or without a hydrogel beneath the dressing, or and alginate dressing, as is appropriate to maintain a moist wound environment while managing exudate; A secondary retention bandage appropriate to the amount of wound exudate, so as to avoid maceration of the peri-wound skin; Off-loading device appropriate to the location of wound with full length boot or total contact cast (unless not appropriate where a substitute off-loading device can be made with sponsor approval); and, Appropriate use of systemic antibiotics.
  • Experimental: Standard of Care + Intervention
    SOC arm with the following modifications: * Consecutive weekly application of PPECM for the 12-week study period. * Subjects will receive no more than 12 applications of PPECM Note: PPECM should be applied after standard wound cleansing and debridement procedures, prior to the application of primary wound dressing, in accordance with the IFU.

Primary Outcome Measure

To determine if PPECM augmented care is superior to SOC in the closure of diabetic foot ulcers at 12 weeks. [ Time Frame: 12 weeks ]

Central Contacts

Locations (9)

FacilityCityStateZIPSite coordinators
Angel City ResearchLos AngelesCalifornia90010
Maira Jackson
(213)-365-0793
Felix Sigal, DPM (PRINCIPAL_INVESTIGATOR)
Center for Clinical ResearchSan FranciscoCalifornia94115
Gayana Sarkisova
800-363-1069
Alexander Reyzelman (PRINCIPAL_INVESTIGATOR)
ILD Research CenterVistaCalifornia92081
Eric Martinez
(760) 350-5080
Dean Vayser (PRINCIPAL_INVESTIGATOR)
Dinamo Research and Diagnostic CenterHialeahFlorida33015
Andres Perez
(786)-536-2425
Ramon Sastre (PRINCIPAL_INVESTIGATOR)
Indiana Foot & AnkleJasperIndiana47456
Tennille Siddons
812-634-2778
Andrew Rader, DPM (PRINCIPAL_INVESTIGATOR)
US-FASHagerstownMaryland21742
Kimberley Shrewsbridge
301-531-5290
Brandy Grahn (PRINCIPAL_INVESTIGATOR)
Boston Medical CenterBostonMassachusetts02118
Connor Roddy
617-414-6839
Vitaly Volansky (PRINCIPAL_INVESTIGATOR)
Northwell Health Comprehensive Wound Healing CenterNew Hyde ParkNew York11042
Sally Kaplan
(516) 562-4578
Alisha Oropallo (PRINCIPAL_INVESTIGATOR)
US-FASRaleighNorth Carolina27609
Allison Denton
(919) 213-0261
Alan Boehm (PRINCIPAL_INVESTIGATOR)

Find similar trials in Los Angeles, CA

Related Studies